ArticleBlood advances2026
LyP vs advanced-stage CTCLs: single-cell profiling reveals markers of self-limited vs aggressive disease behavior.
Article in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
abstractCutaneous T-cell lymphomas (CTCL) encompass a broad spectrum from highly indolent to aggressive systemic disease, but underlying mechanisms remain only poorly understood. Using single-cell RNA sequencing, we profiled samples from patients with self-limited, spontaneously regressing lymphomatoid papulosis (LyP) lesions of CD4+, CD8+, or T-cell receptor γδ (TCR-γδ)+ clonal phenotypes and compared the results with samples from patients with advanced-stage CTCL (aCTCL) variants, namely CD4+ mycosis fungoides (MF), CD8+ primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma, and TCR-γδ+ MF, that all led to a documented lethal disease outcome. Within T cells, transcriptomic differences between LyP and the aCTCL group were primarily found among malignant clones, with only relatively minor differences within the polyclonal T-cell infiltrates. When compared with all aCTCL diagnoses, LyP top clones consistently exhibited a hyperactivated cytotoxic phenotype, characterized by the enrichment of tumor necrosis factor α (TNF-α), interleukin-2 (IL-2)/STAT5, interferon gamma, hypoxia, and complement activation pathways, irrespective of their CD4, CD8, or TCR-γδ lineage. In line, LyP lesions contained SPP1+ macrophages expressing M1-associated markers (IL1B, TNF, and IRF1), consistent with a cytotoxic, type 1-skewed immune microenvironment, that were largely absent across aCTCL diagnoses. LyP samples further expressed markers of vascular dysfunction and stress (C2CD4B, IL6, and CEBPD), corroborated by the morphological signs of lymphocytic vasculitis and necrosis in a subset of patients. Along with a signal of an insufficient coping response to hypoxia, these stromal reactions might be critical contributors to spontaneous lesion regression in LyP. Collectively, this study reveals mediators associated with the self-limited behavior of LyP lesions, which might be relevant for future immunomodulatory treatment strategies in CTCL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.